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Antiphospholipid syndrome (APS) is a disease char-
acterized by the hypercoagulable state with clinical
manifestation of venous and arterial thrombosis and
fetal loss [1,2]. The diagnosis is made according to
clinical findings and one of the two laboratory crite-
ria including positive anticardiolipin antibody (aCL)
and lupus anticoagulant (LA) [3]. Nevertheless, several
observations indicate that the coagulation system is
triggered, as shown by the inhibition of physiologic
anticoagulants and the inhibition of fibrinolysis [4–7].
The inhibition of both protein C activation by throm-
bin and thrombomodulin and of proteolytic cleavage
of factor Va and factor VIIIa by activated protein C
has been observed in association with APS [8–10].
Autoantibodies to vascular heparin sulfate proteogly-
can can block the activation of natural anticoagulant
antithrombin III [11–13]. In addition, there is some evi-
dence of increased plasminogen activator inhibitor-1
[14] and the autoantibody on factor XII-dependent
fibrinolysis [15,16].
Under resting conditions, endothelial cells exhibit
the property of an anticoagulant, which keeps ves-
sels patent with uncoagulated blood. After vascular 
damage or inflammation, endothelial cells play an
important role in triggering the coagulation system.
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Antiphospholipid syndrome (APS) is an antibody-mediated hypercoagulable state characterized
by recurrent venous and arterial thromboembolic events. The presence of serum antibodies are
collectively termed as antiphospholipid antibodies (aPL) and is the hallmark of the disease. Interest
in the pathogenesis has mostly been focused on the blood coagulation factor. However, endothe-
lial cells might play an important role. When stimulated, cell membrane would flip to expose
negatively charged phospholipids and activation markers such as adhesive molecules may appear.
We consider that these changes may play an important role in the initiation of the thrombotic
process when endothelial cells encounter aPL. In this study, we incubated human umbilical vein
endothelial cells (HUVECs) with IgG isolated from patients with APS and found that the
HUVECs were activated by the expression of negatively charged phospholipids, as shown by
high annexin V binding and negative propidium iodide staining and by an increase in the level 
of intracellular cell adhesion molecule-1 on the cell surface. The above findings indicate that
endothelial cells can be activated on exposure to aPL and trigger the thrombotic event.
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Despite much attention being focused on the blood
components of the coagulation system in APS patients,
we think that in the presence of antiphospholipid anti-
bodies (aPL), endothelial cells may show some changes
to unclothe the anticoagulant state and promote the
process of hypercoagulation.
MATERIALS AND METHODS
Patients
Five patients from outpatient clinics of the Rheumato-
logy Division, Kaohsiung Medical University Hospital,
who fulfilled classification criteria for APS (Sapporo
criteria [3]) were enrolled in the study. All patients were
either positive for LA, aCL or anti-β2-glycoprotein-1
(β2-GP-1). The age of the five patients ranged from 
20 to 44 years (mean, 27 years) (Table 1). This study
was approved by the medical ethics committee 
of Kaohsiung Medical University Hospital, and all
patients signed a consent form.
Purification of IgG
Immunoglobulin G (IgG) was isolated from the sera
of APS patients by protein G sepharose (Amersham,
Uppsala, Sweden). The protein concentration of the
purified antibodies was determined by Bradford assay
and sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis. The isolated IgG was further concen-
trated by the use of Amicon Ultra-4 (Millipore Corp.,
Billerica, MA, USA) with centrifugation at 4000g for 10
minutes. The concentrate was then filtered by 0.22 μm
microporous membrane (Millipore Corp.) to make it
sterile.
Cells
Human umbilical vein endothelial cells (HUVECs)
were isolated from the umbilical veins of normal term
deliveries as described previously [17]. Briefly, the
vein was rinsed with phosphate-buffered saline
(PBS) and then with Hank’s balanced salt solution
(Sigma Chemical Co., St Louis, MO, USA) through
19-gauge drawing-up needles secured into the vein.
Then, 0.1% collagenase Type IV (Sigma Chemical
Co.) was introduced into the umbilical vein and the
cord was submerged in warm cord buffer and incu-
bated at 37°C in a humidified 5% CO2 at atmosphere
for 15 minutes. The collagenase solution containing
HUVECs was aspirated from the vein, and cen-
trifuged twice at 1,000 rpm for 5 minutes. HUVECs
contained in this pellet were resuspended in Iscove’s
Modified Dulbecco’s Medium (Biological Industries
Ltd., Kibbutz Beit Haemek, Israel) containing 
10 μg/mL of endothelial cell growth supplement
(Upstate Biotechnology Inc., Lake Placid, NY, USA),
10% fetal calf serum (Biological Industries Ltd.), 
10μg/mL of insulin (Sigma Chemical Co.), and 33 mM
3-isobutyl-1-methylxanthine (Sigma Chemical Co.),
0.1% antibiotics (penicillin, streptomycillin, ampho-
tericin). HUVECs were then seeded into a sterile 
75 cm2 culture flask (NUNC A/S, Roskilde, Denmark)
that had been coated with 0.8% gelatin (Merck,
Darmstadt, Germany). The culture medium was
changed every other day and the culture continued
in a humidified 5% CO2 atmosphere until 80% con-
fluence was reached. HUVECs were only used from
passages 2–3 in this study.
Flow cytometry
HUVECs were seeded at 4 ˜ 105 cells/mL density on
48-well plates (Costar/Corning, Acton, MA, USA)
for flow cytometry. After the 6-hour treatment of APS
IgG (1 mg/mL), cells were harvested and washed in
PBS. After resuspension in 100 μL of annexin V bind-
ing buffer (10mmol/L HEPES, 140mmol/L NaCl,
2.5 mmol/L CaCl2, pH 7.4; Molecular Probes Inc.,
Table 1. Clinical and laboratory data in five antiphospholipid syndrome patients
Patient Sex Age (yr) Clinical diagnosis aPL test
1 F 24 SLE, CVA (artery thrombosis) aCL(+/–), LA(+), anti-β2-GP-1(+)
2 F 31 Vasculitis, abortion aCL(+/–), LA(+), anti-β2-GP-1(+)
3 F 44 SLE, venous thrombosis aCL(+)
4 F 20 MCTD, artery thrombosis aCL(+)
5 F 30 SLE, abortion LA(+), anti-β2-GP-1(+)
aPL = antiphospholipid antibody; SLE = systemic lupus erythematosus; CVA = cerebrovascular accident; aCL = anticardiolipin anti-
body; LA = lupus anticoagulant; anti-β2-GP-1 = anti-β2-glycoprotein-1; MCTD = mixed connective tissue disease.
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Eugene, OR, USA), samples were stained with 2 μL of
annexin V–fluorescein isothiocyanate (FITC) (Strong
Biotech Corp., Taiwan) together with 1 mg/mL of
propidium iodide, and incubated for 15 minutes.
Intracellular cell adhesion molecule-1 (ICAM-1) was
detected by adding 2 μL phycoerythrin (PE) conjugate
ICAM-1 (CD54; BioLegend Inc., San Diego, CA, USA)
for 30 minutes. Analysis was performed on a FACScan
flow cytometry (Partec GmbH, Münster, Germany)
equipped with FloMax software. For each sample,
10,000 events were collected and mean fluorescence
intensity (MFI) was analyzed (Table 2).
RESULTS
Changes in cell membrane phospholipids
When HUVECs were cultured in the presence of IgG
isolated from the five patients, the cell membrane
expressed more negatively charged phospholipids in
their outer layers, which was represented by stronger
annexin V binding. In addition, the negative staining
of the cells by propidium iodide indicated that the
nuclear membranes were still intact (Figure 1, Table 2).
Expression of adhesive molecules
To test whether the endothelial cells were activated
by the antibodies, we further analyzed the expression
of the adhesion molecule ICAM-1 on the cell surface
when the cells were exposed to IgG isolated from the
patients. All five IgGs isolated from the patients
increased the surface expression of ICAM-1 (Figure 2,
Table 2).
Table 2. Expression of annexin V and intracellular cell
adhesion molecule-1 (ICAM-1) and cell viability of
human umbilical vein endothelial cells after incubation
with antiphospholipid antibody-containing immuno-
globulin G purified from five patients with antiphos-
pholipid syndrome
Annexin V PI ICAM-1
MFI % MFI MFI %
Untreated 1.65 32.94 0.26 0.74 17.95
Patient 1 4.81 51.60 3.31 1.40 32.96
Patient 2 7.13 67.26 0.26 5.63 66.98
Patient 3 9.65 55.36 0.24 8.70 72.08
Patient 4 6.71 52.27 0.25 13.27 52.99
Patient 5 5.86 53.74 0.26 7.56 59.87
PI = propidium iodide; MFI = mean fluorescence intensity;
% = percentage of positive cells.
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Figure 1. Effects of antiphospholipid antibody-containing immunoglobulin G (IgG) purified from antiphospholipid syndrome (APS)
patients on: (A) annexin V expression; and (B) cell viability detected by flow cytometry. (A) After incubation of human umbilical vein
endothelial cells with IgG isolated from five patients with APS, the expression of negatively charged phospholipids on the cell surface
increased, which was detected by increased annexin V–fluorescein isothiocyanate binding. (B) At the same time, the intact nuclear
membrane, detected by propidium iodide, denotes that the cells are still alive.
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DISCUSSION
APS is characterized by hypercoagulation. Besides
the influence of antibodies on the blood components
including coagulation factors, cofactors, protein C
and protein S have been reported in many papers
[18,19]. We thought that antibodies might trigger the
procoagulant components of endothelial cells and
hence start the coagulation cascade. Our study found
that when exposed to IgGs, the cell membrane began
to increase the expression of negatively charged
phospholipid on their outer layers. There are two
possibilities when a cell has increased expression of
negatively charged phospholipids on the cell mem-
brane but has an intact nuclear membrane: apoptosis
and cell activation. When apoptosis begins, the first
sign is cell membrane flipping the inner layer of
phospholipid bilayers out [20]. When the condition
deteriorates, the cell membrane would further dis-
rupt and encircle some cytoplasmic content to pro-
duce apoptotic bodies. On the other hand, when
endothelial cells are activated, they express adhesive
molecules for further interaction with intravascular
cells such as white blood cells and platelets [18]. In our
experiment, the increased expression of ICAM-1 on
HUVECs in addition to membrane flipping indicated
that the cells were activated and not in an apoptotic
state. However, the possibility exists that after cell
activation, the endothelial cell may progress to cell
death, the so-called “activation-induced cell death”.
No matter what happens after cell activation, nega-
tively charged phospholipids are already exposed,
and the increased negative charge on the cell surface
is the key factor initiating the intrinsic pathway of the
coagulation system, and the high affinity of β2-GP-1
to negatively charged phospholipids is considered to
be the triggering mechanism for the development of
anti-β2-GP-1, which is specific for autoimmune dis-
ease associated APS [21,22].
There are a variety of aPL. The epitopes of target
antigens vary among different clones of antibodies.
Some patients’ antibodies are reactive only with car-
diolipin, while others react with reagents of Venereal
Disease Research Laboratory, LA, and even with
some coagulation factors [23–25]. Antibodies are not
always cross-reactive. Based on high heterogeneity of
antigens, it is not possible to purify these antibodies
by using a single antigen such as cardiolipin. As in
many other reports, we used purified IgG from APS
patients as the source of aPL [26–28]. The limitation
of our study is that no healthy control serum or IgG
was used. In another experiment, however, we found
that when IgG from patients and antiphospholipid
monoclonal antibodies were compared, IgG from
normal controls had no impact on endothelial cells in
the expression of procoagulant-anticoagulant mole-
cules such as thrombomodulin, or von Willebrand fac-
tor (paper in submission). We believe that the above
changes are specific.
Many surface components of endothelial cells, such
as thrombomodulin, protein C, and von Willebrand
factor, are involved in the balance between antico-
agulation and thrombosis [29–33]. Further work must
be done to clarify which factors play critical roles after
the impact of antibodies on endothelial cells and, if
possible, to characterize the different targets among
different clones of antibodies. Above all, we conclude
that apart from the alteration of blood components
after reaction with antibodies, endothelial cells also
take part in the initiation of thrombosis when exposed
to antibodies.
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Figure 2. Effect of antiphospholipid antibody-containing
immunoglobulin G (IgG) purified from antiphospholipid syn-
drome (APS) patients on intracellular cell adhesion molecule-1
(ICAM-1) expression of human umbilical vein endothelial cells
(HUVECs) detected by flow cytometry. After incubation of
HUVECs with IgG isolated from five patients with APS, the
expression of adhesion molecule ICAM-1 on the cell surface
increased, as detected by increased anti-ICAM-1-phycoerythrin
(PE) binding. The black line is the negative control.
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